Predicting Immunotherapy Response with IPS and TIDE

In the immunotherapy response analyses, immunophenoscore (IPS) was a superior predictor of response to anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) and anti-programmed cell death protein 1 (PD-1) antibodies [25 (link)]. IPS, available through The Cancer Immunome Atlas (TCIA) (https://tcia.at/), is developed from four categories: effector cells (activated CD4 + T cells, activated CD8 + T cells, effector memory CD4 + T cells, and effector memory CD8 + T cells), suppressive cells (Tregs and MDSCs), MHC-related molecules, and checkpoints or immunomodulators. Tumor Immune Dysfunction and Exclusion (TIDE) was calculated online (http://tide.dfci.harvard.edu/) and had potential clinical efficacy to assess the responsiveness of patients in different risk groups to immune checkpoint inhibitors (ICIs) therapy. The TIDE score is superior to recognized immunotherapy biomarkers (PD-L1 level, and interferon γ) for assessing anti-PD1 and anti-CTLA4 effectiveness. The responses to chemotherapy and target therapy were assessed using the “pRRophetic” package based on the Genomics of Drug Sensitivity in Cancer (GDSC) website (https://www.cancerrxgene.org/). A lower half-maximal inhibitory concentration (IC50) referred to a higher sensitivity to the drug treatment.